Pediatric Drugs

, Volume 9, Issue 4, pp 249–266 | Cite as

Atypical Antipsychotics in Children with Pervasive Developmental Disorders

  • Benjamin Chavez
  • Mapy Chavez-Brown
  • Michael A. SopkoJr
  • Jose A. Rey
Review Article

Abstract

The treatment of pervasive developmental disorders (PDDs) is a challenging task, which should include behavioral therapy modifications as well as pharmacologic therapy. There has been a lack of data on using medications in children with PDDs until recent years. Within the last 10 years, an increase in clinical research has attempted to provide efficacy and safety data to support the use of medications in children with PDDs. Double-blinded and open-label research of atypical antipsychotics has been of particular focus.

Evidence shows that atypical antipsychotics (AAs) may be useful in treating certain symptoms associated with PDDs, such as aggression, irritability, and self-injurious behavior. This article reviews the literature regarding the use of AAs in children with PDDs. Of the AAs, risperidone has the largest amount of evidence with five published double-blinded, placebo-controlled trials and nine open-label trials. These risperidone trials have consistently shown improvements in aggression, irritability, self-injurious behavior, temper tantrums, and quickly changing moods associated with autistic disorder and other PDDs. Data for the other AAs are limited, but ziprasidone and aripiprazole appear to be promising treatment options. Based on clinical trials, olanzapine and quetiapine have shown minimal clinical benefit and a high incidence of weight gain and sedation. It should be noted that all AAs do have a risk of metabolic syndrome, and patients should be monitored appropriately while receiving these medications.

Overall, AAs can be beneficial in alleviating behavioral symptoms, and should be considered an appropriate therapeutic option, as part of a comprehensive treatment strategy, for children with PDD.

References

  1. 1.
    Diagnostic and statistical manual of mental disorders. 4th ed, text revision. Washington, DC: American Psychiatric Association, 2000Google Scholar
  2. 2.
    Corsello CM. Early intervention in autism. Infants Young Child 2005; 18: 74–85CrossRefGoogle Scholar
  3. 3.
    Heward WL. Exceptional children. 8th ed. Upper Saddle River (NJ): Pearson/Merrill Prentice Hall, 2006Google Scholar
  4. 4.
    Frith U. Autism: explaining the enigma. 2nd ed. Oxford: Blackwell, 2003Google Scholar
  5. 5.
    Baron-Cohen S, Wheelwright S. The friendship questionnaire (FQ): an investigation of adults with Asperger’ s syndrome or high functioning autism, and normal sex differences. J Autism Dev Disor 2003; 33: 509–17CrossRefGoogle Scholar
  6. 6.
    Baron-Cohen S, Wheelwright S. The empathy quotient (EQ): an investigation of adults with Asperger’s syndrome or high functioning autism, and normal sex differences. J Autism Dev Disor 2004; 34: 163–75CrossRefGoogle Scholar
  7. 7.
    Centers for Disease Control and Prevention [online]. Available from URL: http://www.cdc.gov/ncbddd/autism/asd_common.htm [Accessed 2006 Oct 1]
  8. 8.
    Connor DF, Meltzer BM. Pediatric psychopharmacology fast facts. New York: W.W. Norton & Company, 2006Google Scholar
  9. 9.
    National Institutes of Health. ‘Autism fact sheet’ NINDS. Bethesda (MD): National Institutes of Health, 2006 Apr. NIH publication no. 06-1877Google Scholar
  10. 10.
    Griffith EM, Pennington BF, Wehner EA, et al. Executive function in young children with autism. Child Dev 1999; 70: 817–32PubMedCrossRefGoogle Scholar
  11. 11.
    Mostofsky S, Dubey P, Jerath VK, et al. Developmental dyspraxia is not limited to imitation in children with autism spectrum disorders. J Int Neuropsychol Soc 2006; 12: 314–26PubMedCrossRefGoogle Scholar
  12. 12.
    Zhao Y, Shen H, Amini R, et al. Control of hippocampal morphogenesis and neuronal differentiation by the LIM homeobox hene Lhx5. Science 1999; 284(5417): 1155–8PubMedCrossRefGoogle Scholar
  13. 13.
    Happe F, Ronald A, Plomin R. Time to give up on a single explanation for autism. Nat Neurosc 2006; 9: 1218–20CrossRefGoogle Scholar
  14. 14.
    Williams DL, Goldstein G, Minshew NJ. The profile of memory function in children with autism. Neuropsychol 2006; 20(1): 21–9CrossRefGoogle Scholar
  15. 15.
    Durand CM, Betancur C, Boeckers TM, et al. Mutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autism spectrum disorders. Nat Genet 2007; 39: 25–7PubMedCrossRefGoogle Scholar
  16. 16.
    Brune CW, Kim SJ, Salt J, et al. 5-HTTLPR genotype-specific phenotype in children and adolescents with autism. Am J Psychiatry 2006; 163: 2148–56PubMedCrossRefGoogle Scholar
  17. 17.
    The Agency for Toxic Substances and Disease Registry. Contaminants of concern [online]. Available from URL: http://www.atsdr.cdc.gov/HAC/pha/bri/bri_p4.html#a [Accessed 2006 Oct 1]
  18. 18.
    Geier MR, Geier DA. Thimerosal in childhood vaccines, neurodevelopment disorders, and heart disease in the United States. J Am Physicians Surgeons 2003; 8(1) [online]. Available from URL: http://www.jpands.org/jpands0801.htm [Accessed 2007 Jul 4]
  19. 19.
    Institute of Medicine of the National Academies. Immunization safety review: vaccines and autism [online]. Available from URL: http://www.nap.edu/catalog.ph-p?.record_id=10997#toc [Accessed 2006 Oct 1]
  20. 20.
    Taylor B. Vaccines and the changing epidemiology of autism. Child Care Health Dev 2006; 32: 511–9PubMedCrossRefGoogle Scholar
  21. 21.
    Fombonne E, Zakarian R, Bennett A, et al. Pervasive developmental disorders in Montreal, Quebec, Canada: prevalence and links with immunizations. Pediatrics 2006; 118: el39–50CrossRefGoogle Scholar
  22. 22.
    Uchiyama T, Kurosawa M, Inaba Y. MMR-vaccine and regression in autism spectrum disorders: negative results presented from Japan. J Autism Dev Disord 2007; 37: 210–7PubMedCrossRefGoogle Scholar
  23. 23.
    National Institute of Neurological Disorders and Stroke. NINDS pervasive development disorders information page [online]. Available from URL: http://www.ninds.nih.gove/disorders/pdd/pdd.htm [Accessed 2007 Feb 14]
  24. 24.
    Smith T, Eikeseth S, Klevstrand M, et al. Intensive behavioral treatment for preschoolers with severe mental retardation and pervasive developmental disorder. Am J Ment Retard 1997; 102: 238–49PubMedCrossRefGoogle Scholar
  25. 25.
    Eikeseth S, Smith T, Jahr E, et al. Intensive behavioural treatment at school for 4 to 7 year old children with autism: a one year comparison controlled study. Behav Modif 2002; 26: 49–68PubMedCrossRefGoogle Scholar
  26. 26.
    Smith T. Outcome of early intervention for children with autism. Clin Psychol Sci Pract 1999; 6: 33–49CrossRefGoogle Scholar
  27. 27.
    Jensen VK, Sinclair LV. Treatment of autism in young children: behavioral intervention and applied behavioral analysis. Infants Young Child 2002; 14: 42–52CrossRefGoogle Scholar
  28. 28.
    Sloam L. Use of medication in pervasive developmental disorders. Psychiatr Clin North Am 1991; 14(1): 165–82Google Scholar
  29. 29.
    Mikkelsen EJ. Efficacy of neuroleptic medication in pervasive developmental disorders of childhood. Schizophr Bull 1982; 8(2): 320–32PubMedCrossRefGoogle Scholar
  30. 30.
    American Diabetes Association. Consensus development conference on anti-psychotic drugs and obesity and diabetes. Diabetes Care 2004; 27: 596–601CrossRefGoogle Scholar
  31. 31.
    Chavez B, Chavez-Brown M, Rey JA. Role of risperidone in children with autism spectrum disorder. Ann Pharmacother 2006; 40: 909–16PubMedCrossRefGoogle Scholar
  32. 32.
    Research Units on Pediatric Psychopharmacology Autism Network. Risperidone in children with autism and serious behavioral problems. N Engl J Med 2002; 347: 314–21CrossRefGoogle Scholar
  33. 33.
    Research Units on Pediatric Psychopharmacology Autism Network. Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months. Am J Psychiatry 2005; 162: 1361–69CrossRefGoogle Scholar
  34. 34.
    Shea S, Turgay A, Carroll A, et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 2004; 114: 634–41CrossRefGoogle Scholar
  35. 35.
    Nagaraj R, Singhi P, Malhi P. Risperidone in children with autism: randomized, placebo-controlled, double-blind study. J Child Neuro 2006; 21(6): 450–5Google Scholar
  36. 36.
    Troost PW, Lahuis BE, Steenhuis MP, et al. Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study. J Am Acad Child Adolesc Psychiatry 2005; 44: 1137–44PubMedCrossRefGoogle Scholar
  37. 37.
    Luby J, Mrakotsky C, Stalets MM, et al. Risperidone in preschool children with autistic spectrum disorders: an investigation of safety and efficacy. J Child Adolesc Psychopharmacol 2006; 16: 575–87PubMedCrossRefGoogle Scholar
  38. 38.
    Hollander E, Wasserman S, Swanson EN, et al. A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. J Child Adolesc Psychopharmacol 2006; 16: 541–8PubMedCrossRefGoogle Scholar
  39. 39.
    Aman MG, Arnold LE, McDougle CJ, et al. Acute and long-term safety and tolerability of risperidone in children with autism. J Child Adolesc Psychopharmacol 2005; 15: 869–84PubMedCrossRefGoogle Scholar
  40. 40.
    Hellings JA, Zarcone JR, Crandall K, et al. Weight gain in a controlled study of risperidone in children, adolescents and adults with mental retardation and autism. J Child Adolesc Psychopharmacol 2001; 11(3): 229–38PubMedCrossRefGoogle Scholar
  41. 41.
    Anderson GM, Scahill L, McCracken JT, et al. Effects of short- and long-term risperidone treatment on prolactin levels in children with autism. Biol Psychiatry 2007; 61: 545–50PubMedCrossRefGoogle Scholar
  42. 42.
    Findling RL, Kusumakar V, Daneman D, et al. Prolactin levels during long-term risperidone treatment in children and adolescents. J Clin Psych 2003; 64: 132–69Google Scholar
  43. 43.
    McDougle C, Scahill L, Aman M, et al. Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. Am J Psychiatry 2005; 162: 1142–8PubMedCrossRefGoogle Scholar
  44. 44.
    Williams SK, Scahill L, Vitiello B, et al. Risperidone and adaptive behavior in children with autism. J Am Acad Child Adolesc Psychiatry 2006; 45(4): 431–9PubMedCrossRefGoogle Scholar
  45. 45.
    Rausch JL, Sirota EL, Londino DL, et al. Open-label risperidone for the Asperger’s disorder: negative symptoms spectrum response. J Clin Psychiatry 2005; 66: 1592–7PubMedCrossRefGoogle Scholar
  46. 46.
    Malone RP, Maislin G, Choudhury MS, et al. Risperidone treatment in children and adolescents with autism: short- and long-term safety and effectiveness. J Am Acad Child Adolesc Psychiatry 2002; 41(2): 140–7PubMedCrossRefGoogle Scholar
  47. 47.
    Diler RS, Firat S, Avci A. An open-label trial of risperidone in children with autism. Curr Ther Res Clin Exp 2002; 63: 91–102CrossRefGoogle Scholar
  48. 48.
    Zuddas A, DiMartino A, Muglia A, et al. Long-term risperidone for pervasive developmental disorder: efficacy, tolerability, and discontinuation. J Child Adolesc Psychopharmacol 2000; 10(2): 79–90PubMedCrossRefGoogle Scholar
  49. 49.
    Nicolson R, Awad G, Sloman L. An open trial of risperidone in young autistic children. J Am Acad Child Adolesc Psychiatry 1998; 37(4): 372–6PubMedCrossRefGoogle Scholar
  50. 50.
    Findling RL, Maxwell K, Wiznitzer M. An open clinical trial of risperidone monotherapy in young children with autistic disorder. Psychopharmacol Bull 1997; 33(1): 155–9PubMedGoogle Scholar
  51. 51.
    McDougle CL, Holmes JP, Bronson MR, et al. Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective open-label study. J Am Acad Child Adolesc Psychiatry 1997; 36(5): 685–93PubMedCrossRefGoogle Scholar
  52. 52.
    Horrigan JP, Barnhill LJ. Risperidone and explosive aggressive autism. J Autism Development Dis 1998; 27(3): 313–23CrossRefGoogle Scholar
  53. 53.
    Fisman S, Steele M. Use of risperidone in pervasive developmental disorders: a case series. J Child Adolesc Psychopharmacol 1996; 6(3): 177–90PubMedCrossRefGoogle Scholar
  54. 54.
    Malone RP, Cater J, Sheikh RM, et al. Olanzapine versus haloperidol in children with autistic disorder: an open pilot study. J Am Acad Child Adolesc Psychiatry 2001; 40: 887–94PubMedCrossRefGoogle Scholar
  55. 55.
    Kemner C, Willemsen-Swinkels SH, DeJonge M, et al. Open-label study of olanzapine in children with pervasive developmental disorder. J Clin Psychopharmacol 2002; 22: 455–60PubMedCrossRefGoogle Scholar
  56. 56.
    Potenza M, Holmes JP, Kanes SJ, et al. Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study. J Clin Psychopharmacol 1999; 19: 37–44PubMedCrossRefGoogle Scholar
  57. 57.
    Martin A, Koenig K, Scahill L, et al. Open-label quetiapine in the treatment of children and adolescents with autistic disorder. J Child Adolesec Pyschopharmacol 1999; 9: 99–107CrossRefGoogle Scholar
  58. 58.
    Findling RL, McNamara NK, Gracious BL, et al. Quetiapine in nine youths with autistic disorder. J Child Adolesc Psychopharmacol 2004; 14: 287–94PubMedCrossRefGoogle Scholar
  59. 59.
    McDougle CJ, Kern DL, Posey DJ. Case series: use of ziprasidone for maladaptive symptoms in youths with autism. J Am Acad Child Adolesc Psychiatry 2002; 41: 921–7PubMedCrossRefGoogle Scholar
  60. 60.
    Stigler KA, Posey DJ, McDougle CJ. Aripiprazole for maladaptive behavior in pervasive developmental disorders. J Child Adolesc Psychopharmacol 2004; 14: 455–63PubMedCrossRefGoogle Scholar
  61. 61.
    Stigler KA, Diener JT, Kohn AE, et al. A prospective, open-label study of aripiprazole in youth with Asperger’s disorder and pervasive developmental disorder not otherwise specified [poster]. New Clinical Drug Evaluator Unit 47th annual meeting; 2007 Jun 11–14; Boca Raton (FL)Google Scholar
  62. 62.
    Geodon® [package insert]. New York: Pfizer, 2007 Mar [online]. Available from URL: http://www.pfizer.com/pfizer/download/uspi_geodon.pdf [Accessed 2007 Jul 18]
  63. 63.
    Zuddas A, Ledda MG, Fratta A, et al. Clinical effects of clozapine on autistic disorder [letter]. Am J Pscyhiatry 1996; 153: 738Google Scholar
  64. 64.
    Chang NC, Bedair HS, McKay B, et al. Clozapine in the treatment of aggression in an adolescent with autistic disorder. J Clin Psychiatry 2001; 62: 479–80CrossRefGoogle Scholar
  65. 65.
    Casaer P, Walleghem D, Vandenbussche I, et al. Pharmacokinetics and safety of risperidone in autistic children [abstract]. Pediatr Neurol 1994; 11(2): 89CrossRefGoogle Scholar
  66. 66.
    Grothe DR, Calis KA, Leslie J, et al. Olanzapine pharmacokinetics in pediatric and adolescent inpatients with childhood-onset schizophrenia. J Clin Psychopharmacol 2000; 20: 220–5PubMedCrossRefGoogle Scholar
  67. 67.
    McConville BJ, Arvantis LA, Thyrum PT, et al. Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumerate: an open-label trial in adolescents with psychotic disorders. J Clin Psychiatry 2000; 61: 252–60PubMedCrossRefGoogle Scholar
  68. 68.
    Sallee FR, Miceli JJ, Tesnfeldt T, et al. Single-dose pharmacokinetics and safety of ziprasidone in children and adolescents. J Am Acad Child Adolesc Psychiatry 2006; 45: 720–8PubMedCrossRefGoogle Scholar
  69. 69.
    Findling RL, Blumer JL, Kaufman R, et al. Aripiprazole in pediatric conduct disorder: a pilot study [poster]. Presented at the 16th Congress of the European College of Neeuropsychopharmacology Meeting; 2003 Sep 20–24; PragueGoogle Scholar
  70. 70.
    Findling RL, Kaufman R, Batterson J, et al. Tolerability of aripiprazole in children and adolescent with major psychiatric diagnoses [poster]. Presented at the American Academy of Child and Adolescent Psychiatry Meeting; 2005 Oct 18–23; Toronto (ON)Google Scholar
  71. 71.
    Frazier JA, Cohen LG, Jacobsen L, et al. Clozapine pharmacokinetics in children and adolescents with childhood-onset schizophrenia. J Clin Psychopharmacol 2003; 23: 87–91PubMedCrossRefGoogle Scholar
  72. 72.
    Anderson GM. Genetics of childhood disorders: XLIV. Autism, part 4: serotonin in autism. J Am Acad Child Adolesc Psychiatry 2002; 41: 1513–6PubMedCrossRefGoogle Scholar
  73. 73.
    Cook EH. Autism: review of neurochemical investigation. Synapse 1990; 6: 292–308PubMedCrossRefGoogle Scholar
  74. 74.
    Anderson GM, Freedman DX, Cohen DJ, et al. Whole blood serotonin in autistic and normal subjects. J Child Psychol Psychiatry 1987; 28: 885–900PubMedCrossRefGoogle Scholar
  75. 75.
    Schain RJ, Freedman DX. Studies on 5-hydroxyindole metabolism in autistic and other mentally retarded children. J Pediatr 1961; 58: 315–20PubMedCrossRefGoogle Scholar
  76. 76.
    Burgess NK, Sweeten TL, McMahon WM, et al. Hyperserotoninemia and altered immunity in autism. J Autism Dev Disord 2006; 36: 697–704PubMedCrossRefGoogle Scholar
  77. 77.
    Aman MG, Madrid A. Atypical antipsychotics in persons with developmental disabilities. MRDD Res Rev 1999; 5: 253–63Google Scholar
  78. 78.
    Richelson E. Preclinical pharmacology of neuroleptics: focus on new generation compounds. J Clin Psychiatry 1996; 57Suppl. 11: 4–11PubMedGoogle Scholar
  79. 79.
    Hunsinger DM., Nguyen T, Zebraski SE, et al. Is there a basis for novel pharmacotherapy of autism? Life Sci 2000; 67: 1667–82PubMedCrossRefGoogle Scholar
  80. 80.
    McDougle CJ, Naylor ST, Cohen DJ, et al. A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry 1996; 53: 1001–8PubMedCrossRefGoogle Scholar
  81. 81.
    Tuchman R. Autism. Neurol Clin North Am 2004; 21: 915–32Google Scholar
  82. 82.
    Anderson GM, Cook EH. Pharmacogenetics: promise and potential in child and adolescent psychiatry. Child Adolesc Psychiatr Clin North Am 2000; 9: 23–42Google Scholar
  83. 83.
    Palermo MT, Curatolo P. Pharmacologic treatment of autism. J Child Neurol 2004; 19: 155–64PubMedGoogle Scholar
  84. 84.
    Veenstra-VanderWeele J, Kim SJ, Lord C, et al. Transmission disequilibrium studies of the serotonin 5-HT2A receptor gene (HTR2A) in autism. Am J Med Genet 2002; 114: 277–83PubMedCrossRefGoogle Scholar
  85. 85.
    Klauck SM, Poustka F, Lesch KP, et al. Serotonin transporter (5-HTT) gene variants associated with autism. Hum Mol Genet 1997; 6: 2233–8PubMedCrossRefGoogle Scholar
  86. 86.
    Nurit Yurmiya N, Pilowsky T, Nemanov L, et al. Evidence for an association with the serotonin transporter promoter region polymorphism and autism. Am J Med Genet 2001; 105: 381–6CrossRefGoogle Scholar
  87. 87.
    Murphy DL, Lerner A, Rudnick G, et al. Serotonin transporter gene: gene, genetic disorders, and pharmacogenetics. Mol Inter 2004; 4: 109–23CrossRefGoogle Scholar
  88. 88.
    Meltzer HY. An overview of the mechanism of action of clozapine. J Clin Psychiatry 1994; 55 (9 Suppl. B): 47–52PubMedGoogle Scholar
  89. 89.
    Moghaddam B. Preferential activation of cortical dopamine neurotransmission by clozapine: functional significance. J Clin Psychiatry 1994; 55 (9 Suppl. B): 27–9PubMedGoogle Scholar
  90. 90.
    Pehek EA, Meltzer HY, Yamamoto BK. Local administration of ritanserin on ICS 205,930 enhances dopamine and serotonin efflux in rat prefrontal cortex [abstract]. Neurosci Abstr 1993; 19: 302Google Scholar
  91. 91.
    Leysen JE, Gommeren W, Eens A, et al. Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther 1988; 247: 661–70PubMedGoogle Scholar
  92. 92.
    McDougle CJ, Posey D. Genetic of childhood disorders: XLIV. Autism, part 3: psychopharmacology of autism. J Am Acad Child Adolesc Psychiatry 2002; 41: 1380–3PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2007

Authors and Affiliations

  • Benjamin Chavez
    • 1
    • 2
  • Mapy Chavez-Brown
    • 3
  • Michael A. SopkoJr
    • 1
  • Jose A. Rey
    • 4
  1. 1.Rutgers, State University of New JerseyPiscatawayUSA
  2. 2.Monmouth Medical CenterLong BranchUSA
  3. 3.Wagner CollegeStaten IslandUSA
  4. 4.Nova Southeastern UniversityFort LauderdaleUSA

Personalised recommendations